Comprehensive Research Report on Global Transportation Management Systems (TMS) Market with New Business Opportunities by Forecast to 2026 – The…

This report titled as Global Transportation Management Systems (TMS) Market, gives a brief about the comprehensive research and an outline of its growth in the market globally. It states about the significant market drivers, trends, limitations and opportunities to give a wide-ranging and precise data and also scrutinizes its growth in the overall markets development which is needed and expected.

The report also summarizes the various types of the Global Transportation Management Systems (TMS) Market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of the Global Transportation Management Systems (TMS) Market has been done to understand the various applications of the products usage and features. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Request Sample Copy of this Report: https://www.theresearchconsultant.com/reports/9582/transportation-management-systems-tms-market-status-and-trend-analysis-2017-2026-covid-19-version-/request

Based on the type of product, the global Transportation Management Systems (TMS) market segmented into

Solution type

Hardware

Services

Based on the end-use, the global Transportation Management Systems (TMS) market classified into

Logistics & Transport

Manufacturing

Commercial

Retail

Based on geography, the global Transportation Management Systems (TMS) market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

JDA Software

Oracle Corporation

Manhattan Associates

Descartes

SAP SE

BluJay

TMW Systems

Omnitracs

ORTEC

HighJump

MercuryGate

One Network Enterprises

Precision Software

CargoSmart

Next Generation Logistics

Get Reasonable Discount on this Premium Report: https://www.theresearchconsultant.com/reports/9582/transportation-management-systems-tms-market-status-and-trend-analysis-2017-2026-covid-19-version-/discount

Key questions answered in the report include:

What will the market size and the growth rate be in 2027?

What are the key factors driving the Global Transportation Management Systems (TMS) Market?

What are the key market trends impacting the growth of the global Transportation Management Systems (TMS) Market?

What are the challenges to market growth?

Who are the key vendors in the Global Transportation Management Systems (TMS) Market?

What are the market opportunities and threats faced by the vendors in the global Transportation Management Systems (TMS) Market?

What are the trending factors influencing the market shares of the Americas, APAC, Europe, and MEA?

What are the key outcomes of the five forces analysis of the Global Transportation Management Systems (TMS) Market?

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how the Global Transportation Management Systems (TMS) Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

For More Information: https://www.theresearchconsultant.com/reports/9582/transportation-management-systems-tms-market-status-and-trend-analysis-2017-2026-covid-19-version-/enquiry

About us:

The Research Consultant A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact Us:

Olive (Sales manager) The Research Consultant

Phone: +91-9545883005

sales@theresearchconsultant.com

https://www.theresearchconsultant.com

Read the original here:

Comprehensive Research Report on Global Transportation Management Systems (TMS) Market with New Business Opportunities by Forecast to 2026 - The...

Posted in Tms

Emerging Neuromodulation Technologies Enabling Growth Opportunities in Mental Health Care – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Emerging Neuromodulation Technologies Enabling Growth Opportunities in Mental Health Care" report has been added to ResearchAndMarkets.com's offering.

The treatment of mental health disorders using pharmaceuticals and psychotherapy are plagued with limitations such as therapy-related adverse effects, and inability to provide effective remission. This has driven the use of neuromodulation techniques for managing these conditions. However, these traditional neuromodulation therapies have their share of drawbacks including invasive profile and therapy-related complications, that have necessitated the development of novel neuromodulation methods that can provide effective relief from mental disorders for the patients, while at the same time are non-invasive, safe, and tolerable.

This growth opportunity-technology (GO-TE) report highlights the innovations in non-invasive neuromodulation technologies being implemented for treating mental health conditions, including transcranial electrical stimulation, transcranial magnetic stimulation, cranial electrotherapy stimulation and other therapies such as transcutaneous vagus nerve stimulation, trigeminal nerve stimulation, and multi-channel simultaneous stimulation. The scope of this GO-TE is global. This GO-TE studies some of the path breaking innovators in this space and their technology readiness levels. The report also discusses the funding, partnerships, and emerging growth opportunities.

Key Topics Covered:

1. Executive Summary

1.1 Scope of the Research

1.2 Research Methodology

2. Industry Overview

2.1 Growing Burden of Mental Health Disorders Globally

2.2 Neuromodulation Techniques Address the Limitations of Drug-based and Psychotherapy Methods for Managing Mental Disorders

2.3 Drawbacks of Traditional Neuromodulation Methods are Hindering their Wide-spread Adoption

2.4 Technology Segmentation for Emerging Neuromodulation Therapies

2.5 Transcranial Electrical Stimulation Enabling Neuromodulation of Specific Cortical Regions of the Brain

2.6 Transcranial Magnetic Stimulation Facilitates Neuromodulation of Wide and Deeper Subcortical Structures in the Brain

2.7 Enabling Neuromodulation of Cortical and Subcortical Areas in the Brain through Cranial Electrotherapy Stimulation

2.8 Neuromodulation of Vagus, Occipital, and Trigeminal Nerve for Treating Mental Disorders

2.9 Application Analysis: Increasing Application Areas Offer Lucrative Growth Opportunities for Companies Developing Emerging Neuromodulation Technologies

2.10 Benchmarking Rubrics

2.11 Impact of TMS to be Relatively High as Compared to Other Emerging Neuromodulation Technologies

3. Companies to Action

3.1 Transcranial Direct Current Stimulation System for Managing Depression

3.2 Other Notable Transcranial Direct Current Stimulation Systems for Treating Depression

3.3 Transcranial Magnetic Stimulation System for Managing Depression and Obsessive-compulsive Disorder

3.4 Other Notable Transcranial Magnetic Stimulation Systems for Depression Treatment

3.5 Over-ear Headphone-based Cranial Electrotherapy Stimulator Device for the Treatment of Anxiety, Depression, and Insomnia

3.6 Other Notable Cranial Electrotherapy Stimulation Systems for Treating Anxiety and Depression

3.7 External Trigeminal Nerve Stimulation System for Treating Attention-deficit/Hyperactivity Disorder in Patients

3.8 Other Notable Non-invasive Vagus Nerve Stimulation and Multi-channel Brain Neuromodulation Systems for Managing Mental Disorders

4. Funding and Partnerships Assessment

4.1 Analysis of National Institutes of Health (NIH) Funding for Emerging Neuromodulation Technologies

4.2 Funding Assessment for Emerging Neuromodulation Technologies

4.3 Partnerships between Mental Health Companies and Health Providers for Improving Access to Neuromodulation Therapies

4.4 Acquisitions by Mental Health Neuromodulation Participants for Improving Intellectual Property and Product Portfolio

5. Growth Opportunities and Patent Analysis

5.1 Growth Opportunity: Emerging Neuromodulation Technology Innovations, 2020

5.2 Growth Opportunity 1: Distance Health Facilitated through Wearable-enabled Neuromodulation Therapies

5.3 Growth Opportunity 2: Incorporating Artificial Intelligence into Neuromodulation Systems for Providing Smart Therapy

5.4 Growth Opportunity 3: Partnerships between Non-invasive Neuromodulation Therapy Companies and Specialized Mental Health Providers to Improve Access to Underserved Populations

5.5 Patent Scenario-Key Patents for Transcranial Magnetic Stimulation Systems

5.6 Patent Scenario-Key Patents for Transcranial Electrical Stimulation and Trigeminal Nerve Stimulation Systems

6.0 Key Contacts

For more information about this report visit https://www.researchandmarkets.com/r/ca1m7i

See the rest here:

Emerging Neuromodulation Technologies Enabling Growth Opportunities in Mental Health Care - ResearchAndMarkets.com - Business Wire

Posted in Tms

Small Fleets Drive EKA Cloud-Based TMS Growth – Heavy Duty Trucking

EKA Solutions said it's seeing strong growth in its small-fleet target market.

Photo: Jim Park

As the supply chain increasingly moves toward greater interconnectedness and visibility between carriers, brokers, and shippers, EKA Solutions said 2021 has already started out strong with adoption of its cloud-based integrated freight management ecosystem.

EKA Omni-TMS for carriers is a transportation management system designed to give small and medium-size carriers the ability to compete with large fleets.

"In just three months, a rapidly increasing number of small carriers have adopted the EKA Omni-TMS, empowering these companies to tech up for the future, said J.J. Singh, founder and CEO, in a news release.

He told HDT that at least 33% new customer growth expected in the first quarter of this year compared to the fourth quarter of 2020.

EKAs goal was to target a diverse group of small-fleet customers for its TMS, typically those operating 30 trucks or less. Rapid acceptance confirms our market assumptions were correct, which is very gratifying, Singh told HDT.

These customers cover a diverse range of businesses, he said, including long haul, medium and short haul freight, using all classes of trucks, and with equipment including dry van, temperature-controlled, flatbed, bulk and livestock.

Although the COVID-19 pandemic negatively affected its business in the first half of 2020, Singh said things turned positive in the second half of the year as the economy and freight business environment improved.

This year, EKA is targeting an exponential growth in revenue, Singh said. All of its TMS and visibility products are being continually enhanced, he said, and EKA will introduce Shipper TMS for small- and medium-size shippers in 2021.

Also, in 2021, EKA will integrate its supply chain TMS with third-party services to deliver key services at affordable prices to small and medium size carrier, broker and shipper customers.

EKA TMS is helping small carriers transport all types of commodities, enabling them to handle different customer pricing methods, fluidly pay drivers and settle with owner-operators, and provide complete freight movement visibility to their customers and trusted partners at affordable technology stack and operating costs, said EKA President Mark Walker in the news release.

See the article here:

Small Fleets Drive EKA Cloud-Based TMS Growth - Heavy Duty Trucking

Posted in Tms

Denton County cancels Thursdays vaccination clinic at Texas Motor Speedway due to weather – The Dallas Morning News

Thursday afternoons vaccine mega hub at Texas Motor Speedway has been canceled due to the likelihood of inclement weather, Texas Motor Speedway officials said Tuesday.

Denton County and TMS have been in contact with the National Weather Service since Monday. With a forecast predicting freezing temperatures and a chance of freezing rain and sleet in the early-morning hours, organizers made the decision to postpone.

We do not want to bring our residents out on icy roads or have our crews and volunteers working in below-freezing weather, Denton County Judge Andy Eads said in a news release.

Those who would have had appointments Thursday will be scheduled for Friday afternoon. Denton County Public Health plans to administer approximately 3,000 second doses of the Moderna vaccine, as well as 4,500 first doses of the Pfizer vaccine.

The appointment-only clinics hours will be noon to 4:30 p.m. Friday; originally, the clinic was set for all day.

Appointment times will be sent by Wednesday evening via email and text message to individuals awaiting their second dose, as well as those next on the Vaccine Interest Portal waitlist for first-dose scheduling.

We are hopeful the weather will be more cooperative Friday for a safe, efficient and effective vaccine clinic, Matt Richardson, director of the county health department, said in the release.

Additional appointments will be scheduled for next week at the TMS vaccination hub, which Denton County plans to operate weekly, a spokeswoman said Monday.

Here is the original post:

Denton County cancels Thursdays vaccination clinic at Texas Motor Speedway due to weather - The Dallas Morning News

Posted in Tms

40% of TMS teachers are vaccinated – Saipan Tribune

Privacy Settings

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

Advertising

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Preferences

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Marketing

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Necessary

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.

You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

See original here:

40% of TMS teachers are vaccinated - Saipan Tribune

Posted in Tms

Therapy for OCD: Treatment, Medication, Cost – Healthline

Obsessive compulsive disorder (OCD) is a condition in which people experience unwelcome and distressing thoughts (obsessions) over and over again.

To reduce the anxiety that these thoughts cause, people with OCD often feel they have to perform particular actions (compulsions). Some people with OCD also have motor or vocal tics, like throat-clearing and eye blinking.

Data from a national study conducted by Harvard Medical School shows that OCD is not uncommon: Around 2.3 percent of the population experiences OCD at some point in their lifetime.

OCD is a long-term condition that can get in the way of important daily activities, like work or school, and may also affect relationships.

While there arent any cures yet, there are treatments that can help ease OCD symptoms. In this article, well look at what these treatment options entail.

Many people who experience OCD symptoms never seek treatment, perhaps because symptoms can come and go and they can vary in severity over a lifetime.

With OCD, getting treatment early on is usually the best course of action. Outcomes tend to be more successful with early intervention and appropriate care.

Outcomes are also better when treatment is provided by an interdisciplinary healthcare team. This can include doctors, psychologists, psychiatrists, psychiatric nurses, and pharmacologists who work together to create a treatment plan that meets your individual needs.

For many people, cognitive behavioral therapy (CBT) is an effective way to treat the symptoms of OCD, with or without medication.

CBT is a type of talk therapy that focuses on identifying and changing unhealthy and unrealistic thought patterns.

If you have OCD, youre probably familiar with this cycle: You have an intrusive thought which sparks anxiety. The more you try to control or suppress the thought, the worse the anxiety grows. You may resort to rituals or compulsive behaviors to try and neutralize the threat posed by the unwelcome thoughts.

With CBT, you and your therapist talk about the thoughts that trigger your anxiety. You may:

Newer types of CBT include acceptance and commitment therapy, which helps you view thoughts and feelings including anxiety as temporary experiences that dont need to be controlled.

Learning to separate yourself from your thoughts is a key part of this therapeutic approach, as is committing to a life based on your lasting values rather than fleeting thoughts and feelings.

Researchers are finding that online CBT programs can be as effective for some people as in-person therapy sessions.

Exposure and response prevention (ERP) therapy addresses the underlying fears of both obsessions and compulsions. Early in your therapy sessions, your therapist will educate you about OCD and equip you with skills you can use to reduce anxiety.

Your therapist will also help you identify the situations and events that trigger obsessive thoughts and anxiety. Theyll help you figure out whether these events are related to people, things, places, feelings, or sensory stimuli, such as smells or sounds.

Your therapist will usually give you an opportunity to describe the actions you feel compelled to perform and how these compulsions are related to the fears you feel. Once youve identified your triggers, your therapist will help you rank them according to how upsetting they are.

Over time, you and your therapist will gradually confront each of your fears, starting with the least upsetting. This will allow you to practice calming yourself with the skills youve learned.

The goal is for you to be able to reduce your anxiety on your own which, in turn, may help lessen the need for rituals and compulsions to ease your fear.

Not everyone who starts a course of ERP sticks to it. But for those who do, research shows that ERP can be a very effective method of breaking the connection between obsessive thoughts and compulsions.

If youre diagnosed with OCD, your doctor or healthcare provider may prescribe medication to help you manage your symptoms.

The most effective medications are a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). Among the most commonly prescribed are:

It can take time for these medications to build up in your system to an effective level. Some research shows that you may get the best results if you take the medication consistently for a year or more.

The tricyclic antidepressant clomipramine has also been well studied and has shown to be effective at reducing OCD symptoms. Although its effective, the side effects are more extensive for some people.

If youre taking medication to treat OCD symptoms, its important that you talk to your healthcare provider before you stop or reduce the amount you take. Stopping or reducing your dose too quickly can have harmful effects.

With brain stimulation therapy, doctors use either magnetic or electrical pulses to change activity in areas of the brain known to affect OCD symptoms.

The scientific evidence on the effectiveness of deep brain stimulation is mixed. Because of the invasive nature of this therapy, most doctors agree that it should only be considered if psychotherapy or medication cant help reduce OCD symptoms.

With deep brain stimulation, a doctor places a very thin electrode into an area of your brain known to be involved with OCD.

Once the electrode is in place, small electrical pulses can be used to stimulate the brain. If stimulation doesnt relieve symptoms, the electrode can be removed or re-implanted in another area in the brain.

Brain stimulation therapies have been used to treat OCD since the mid-1980s. Ongoing research is enabling doctors to more precisely target areas of the brain that are related to particular symptoms.

Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique thats shown some promise for treating OCD.

With TMS therapy, a physician sends a current of energy through a magnetic coil thats placed on your head, usually near your forehead. The magnetic pulse thats delivered is thought to stimulate nerve cells in your brain that are associated with OCD symptoms.

At present, TMS is considered an adjunct therapy. This means that its used along with medications to reduce symptoms.

More research is needed to understand how this therapy works and which areas of the brain to target for best results.

OCD can cause a lot of stress. Whatever treatment approaches you and your healthcare team decide to take, it may be helpful to also learn more about how to lower your stress levels.

The following stress management techniques are all effective ways to help calm your mind and body:

When youre dealing with a challenging condition like OCD, taking care of your overall health is especially important. Some steps you may want to take to optimize your health include:

Self-care strategies like these may seem like a tall order when youre grappling with a mental health issue. If you feel overwhelmed by the self-care to-do list, its OK to just pick one healthy habit and practice it when you can.

You dont have to deal with OCD symptoms on your own. A good therapist can be a transformative and empowering ally.

Here are some things to keep in mind if you decide to look for a therapist:

Though many forms of therapy can be completed in 8 to 12 weeks, treating OCD takes time. And when it comes to healthcare, time often translates into cost.

Most private health insurance plans, including those you may access through your employer, do cover some kinds of mental healthcare. Some employers also provide employee assistance programs that feature counseling for mental health conditions.

Medicare Part A, most Medicare Advantage (Medicare Part C) plans, and Medicaid all offer treatment for mental health conditions.

If you dont have access to healthcare coverage, you may want to look for a therapist whose rates are based on your income level or who offers a sliding scale for fee payments.

Good Therapy and the Open Path Psychotherapy Collective both offer search tools that can connect you to therapists who may offer reduced rates. Many community health centers also provide free or low-cost mental health services.

OCD is a mental health condition with symptoms that can disrupt your life. The good news is that there are treatments that can help ease anxiety, reduce intrusive thoughts, and help manage compulsive behaviors.

Behavioral therapies and antidepressant medications are the tried-and-true treatment methods for OCD. There are also other options that may improve your quality of life, although more research is needed to determine how effective they are.

As you explore treatment options, its also important to do what you can to help lower your stress levels and to take good care of your overall health.

More:

Therapy for OCD: Treatment, Medication, Cost - Healthline

Posted in Tms

New Dawn TMS Psychiatry with Their FDA Approved TMS Therapy Offers Holistic Psychiatric Care – Press Release – Digital Journal

The mental health professionals at the facility can help heal all types of severe mood disorders like bipolar disorder through medication monitoring, psychotherapy, and other mental health treatment options.

Los Angeles, CA - New Dawn TMS Psychiatry is a mental wellness clinic that offers a holistic approach to mental health. The clinic provides effective treatments to specifically help with medications, clinical evaluations, and psychotherapy. A chronic and severe mood disorder can significantly alter an individual's ability to lead a normal life. A facility like New Dawn TMS Psychiatry in Los Angeles provides support and help by offering a unique and comprehensive psychiatric management program that offers personalized care. They offer the most innovative and comprehensive care by simplifying the stigma associated with mental illness.

The mental health professionals at the facility can help heal all types of severe mood disorders like bipolar disorder through medication monitoring, psychotherapy, and other mental health treatment options. They utilize pharmacological and non-pharmacological tools to manage symptoms and help patients become emotionally stable. The four main areas where New Dawn TMS Psychiatry focuses on are psychiatric evaluations, medication management, telehealth/online psychiatry services, and psychotherapy services.

"Our multidisciplinary team uses a whole-person approach to psychiatric care," says Dr. Beltagui, MD of the Clinic. "If you're experiencing depression, bipolar disorder, schizophrenia, anxiety disorders, obsessive-compulsive disorder, or other mental illnesses, New Dawn TMS Psychiatry Los Angeles can help you find relief." "Mental illness has been a taboo area that has been swept under the rug for years. New Dawn TMS Psychiatry in Los Angeles is trying to change the stigma of mental illness by being more open and straightforward about it. Mental illness is just like any other illness and needs to be treated just the same," he added.

The professional staff members at New Dawn TMS Psychiatry in Los Angeles can help patients manage medications, monitor medications, and find and understand their diagnosis amongst a host of other treatment options. The comprehensive care at the clinic is provided by Dr. Beltagui, who is a Board-Certified Psychiatrist excelling in understanding his patients and helping them achieve a holistic life. He utilizes several treatment modalities that help patients with depression, anxiety, and many mental problems.

"Assisting individuals and families in achieving optimal emotional balance - whatever the life challenges - is a life-long journey. We have had individual successes, and we are proud of them. However, we take the long view. Whatever our patients' symptoms and their challenges, we will be here to assist them in the journey. Our goal is to help them achieve their mental wellness goals," says Dr. Beltagui. "Anyone who feels the humiliation or suffering of being judged or discriminated against due to mental illness will find New Dawn TMS Psychiatry in Los Angeles a home away from home," he adds.

New Dawn TMS Psychiatry recognizes that mental illness can be a costly illness to manage and that each person's situation is unique. But being a patient-oriented clinic, they maintain the most competitive rates to ensure every patient can receive holistic care. "New Dawn TMS Psychiatry TMS Therapy Cost Los Angeles is affordable and effective," explains Dr. Beltagui. "Oftentimes, individuals don't seek treatment because of the Psychiatry Cost Los Angeles, which can be quite expensive. However, we offer mental health treatment at the most affordable rates for our patients," he further elaborates.

Committed to improving the quality of life of those who have been battling mental illness, New Dawn TMS Psychiatry Los Angeles offers a new approach to mental health care. Boasting revolutionary TMS Therapy, which is FDA approved, New Dawn TMS Psychiatry, assists patients in getting better by offering effective non-invasive treatment and mental health care.

About New Dawn TMS Psychiatry

Located in Los Angeles, the New Dawn TMS Psychiatry is a mental wellness clinic that uses the most innovative technology and treatment options for all kinds of mental health disorders like depression, anxiety, and more. The facility is a place where the community and patients can find comfort and assistance in their mental health challenges and process. Further, with its innovative TMS Therapy, which is FDA approved, New Dawn TMS Psychiatry is able to offer affordable and effective treatments.

Media Contact

Company Name: New Dawn TMS Psychiatry

Email: info@newdawntmspsychiatry.com

Phone: 323-424-4593

Address: 640 S San Vicente Blvd, Ste 210, Los Angeles, CA 90048-4654

Website: https://www.newdawntmspsychiatry.com/

Media ContactCompany Name: NEW DAWN TMS PSYCHIATRYContact Person: Amr Beltagui, MDEmail: Send EmailPhone: 323-424-4593Address:640 S San Vicente Blvd, Ste 210 City: Los AngelesState: CACountry: United StatesWebsite: http://www.newdawntmspsychiatry.com/

Go here to see the original:

New Dawn TMS Psychiatry with Their FDA Approved TMS Therapy Offers Holistic Psychiatric Care - Press Release - Digital Journal

Posted in Tms

‘Significant’ High Court backing for adjudication in construction – Law Society of Ireland Gazette

What is adjudication?

Adjudication is a 28-day dispute resolution process which can be used to resolve disputes relating to payment under construction contracts. The key steps involved are:

Adjudication is designed to be rapid. It is designed to promote cashflow in the construction industry by giving aggrieved parties a mechanism to get cash in the bank quickly without spending years (and lots of money) in arbitration or court.

This rapid mechanism works, however, only if the courts are willing to enforce decisions made by adjudicators; otherwise, unsuccessful parties would simply ignore decisions made against them.

The adjudicators decision at the centre of this case concerned a payment dispute between Gravity Construction Limited and Total Highway Maintenance Limited (TMS). In short, TMS lost and was ordered to pay Gravity 135,458.92.

TMS did not comply with the decision, and Gravity then issued court proceedings to enforce the decision in the High Court. Gravity relied upon section 6(11) of the 2013 act which states:

The decision of the adjudicator, if binding, shall be enforceable either by action or, by leave of the High Court, in the same manner as a judgement or order of that Court with the same effect and, where leave is given, judgement may be entered in the terms of the decision".

Just before the High Court hearing date, TMS indicated that it was prepared to comply with the adjudicators decision.

The High Court enforced the adjudicators decision by giving an unless order. Paragraph 37 of the judgement summarises it:

An order that the applicant has leave to enforce the adjudicators decision in the same manner as a judgement or order of the High Court, and that judgement is to be entered against the respondent in favour of the applicant in the sum claimed unless the said sum is paid to the solicitors acting on behalf of the applicant within seven days of todays date

In other words, the High Court ordered TMS to comply with the adjudicators decision.

This is the first reported case in which the High Court has put its shoulder behind adjudication by enforcing an adjudicators decision under section 6(11) of the 2013 act.

Without support from the High Court, adjudication awards would not be worth the paper they are written on. The decision is therefore very significant indeed.

That said, the whole point of adjudication is speed. Adjudication is about getting aggrieved parties paid quickly. In this regard, the timelines in Gravity give cause for concern.

The adjudicators decision at the heart of the proceedings was dated 28 April 2020. It took almost nine months to enforce. So, does this protracted timeframe defeat the purpose of adjudication entirely? Well yes, it probably does.

There were a number of reasons why it took so long to enforce the adjudicators decision in Gravity:

The points summarised above might sound familiar to adjudication practitioners who have experience in the UK, where there were similar teething problems.

Ultimately, these were resolved by reforms within the court system. In the UK, the courts now enforce adjudication decisions by way of summary judgment, with enforcement hearings taking place roughly 28 days after a procedural application.

If adjudication is going to become a mainstay in Irish construction, we will need reform within the court system to facilitate this. The courts need to rapidly enforce adjudication awards if the process is to have a long-term future in Ireland.

Another barrier to the uptake of adjudication in Ireland was also touched upon in Gravity. At paragraph 32 of the decision, the High Court briefly touched upon one of the legal arguments raised by TMS to resist enforcement.

In short, TMS put forward an argument that the enforcement proceedings should be stayed (put on hold) pending determination of arbitration proceedings.

In this regard the High Court noted that the propriety of this attempt was open for debate, given the wording of section 6(10) of the act, which says: The decision of the adjudicator shall be binding until the payment dispute is finally settled by the parties or a different decision is reached on the reference of the payment dispute to arbitration or in proceedings initiated in a court in relation to the adjudicators decision.

The UK regime has a similar provision, but, in that jurisdiction, there is no debate as to what it means. It means pay first, argue later. Do what the adjudicator says in the first instance, and if you are unhappy about it, start from afresh in arbitration or court.

For constitutional reasons however, the position might not be as clear-cut in Ireland, so that debate still needs to be had.

I have no doubt that we will see the debate above unfold in the Irish courts in the very near future.

More:

'Significant' High Court backing for adjudication in construction - Law Society of Ireland Gazette

Posted in Tms

Neuro Wellness TMS Centers of America In Coral Springs Offers Breakthrough Treatment Of Depression, Anxiety, and Other Disorders – TAPinto.net

CORAL SPRINGS, FL Theres a medical practice in Coral Springs offering a technological breakthrough in the treatment of major depression, anxiety, post-traumatic stressdisorder (PTSD), and other disorders.

Transcranial Magnetic Stimulation (TMS) Therapy is offered at Neuro Wellness TMS Centers of America located at 9734 West Sample Road.

It is an FDA-approved, non-invasive treatment that has been recognized by the American Psychiatric Association in its Best Practices Guidelines as an effective treatment for depression.

Our newsletter delivers the local news that you can trust.

The safe and effective outpatient treatment is for individuals diagnosed with major depressive disorder (MDD) or similar disorders who have not experienced satisfactory improvement from antidepressant medication.

TMS Therapy differs from traditional drug therapy because it employs MRI-strength magnetic pulses that are targeted only to specific regions of the brain involved in mood regulation areas known to be under-active in those diagnosed with MDD.

TMS Therapy activates and raises the levels of neurotransmitters in the brain dopamine, norepinephrine, and serotonin and can be used in conjunction with medication or as a stand-alone treatment.

In FDA clinical trials, two out of every three patients reported remission or a reduction in depression symptoms after completion of TMS Therapy. Subsequent studies have consistently shown three out of every four patients positively responding to TMS Therapy.

What to expect during TMS Therapy?

Although treatment varies by individual, a typical treatment course consists of:

During treatment, patients relax in a treatment chair and remain awake and alert.

The TMS Therapy device will deliver magnetic pulses to specific areas of your brain known to regulate mood. These pulses will feel like tapping on the scalp. Adjustments can be made by your TMS technician if the tapping is uncomfortable.

Mild headache or scalp discomfort is sometimes experienced at the site of stimulation during or after treatment. An over-the-counter analgesic may be taken to alleviate discomfort. If discomfort persists, the strength of the magnetic field pulses can be reduced to make treatment more comfortable.

After a treatment session, patients can immediately return to their normal routine, including driving.

In clinical trials, most patients experienced a positive response to TMS Therapy by the fourth week of treatment. Some patients may experience results in less time, while others may take longer. It is important to continually discuss any depression symptoms with your TMS technician.

Shelly Lahn is the CEO of Neuro Wellness TMS Centers of America.

The team at Neuro Wellness TMS Centers of America helps patients cultivate a more joyful and fulfilling life with complete psychiatric services offered in a comfortable environment.

Find out more about TMS Therapy at Neuro Wellness TMS Centers of America here: neurowellnesstms.com/services/tms

Learn more about the practice and other therapies by:

- Visiting: neurowellnesstms.com

- Calling 954-210-7254

See the article here:

Neuro Wellness TMS Centers of America In Coral Springs Offers Breakthrough Treatment Of Depression, Anxiety, and Other Disorders - TAPinto.net

Posted in Tms

Connected TMS Technology Is Reaching Mom-and-Pop Carriers – SupplyChainBrain

Many small- to mid-sized U.S. carriers struggle to source loads, streamline business processes and capitalize on new business opportunities despite an ever-growing demand for truckload capacity.

Without direct access to shippers, small carriers often rely on freight brokers or serve under larger carrier networks, resulting in a 15-25% loss of potential revenue.

Profitability has suffered other blows in recent years, including empty miles up to 20%, driver turnover exceeding 100% and increased market fragmentation where most dedicated shipper contracts go to 1% of carriers.

While tools like transportation management systems (TMS), load boards and back-office systems are not new to the trucking industry, they pose a new frontier to small carriers who are more familiar with spreadsheets and whiteboards than advanced technologies and artificial intelligence.

Today, we see a democratization of trucking technology, where A.I. is making trucking more efficient, businesses healthier and drivers happier. We now have the unprecedented ability to gather operational information of hundreds of thousands of drivers and fleets to customize a solution for a carriers specific needs. By addressing the entire business process in one place instead of multiple applications for individual functions, todays connected TMS environment supports even the smallest carriers strategic planning, freight sourcing, procurement, performance management and freight payment and auditing.

The Power of Data

The more data thats collected from connected TMS users, the greater the opportunity for optimization, savings, profitability and growth. Data can tell carriers which loads match best within their driver network, which roads are most congested and which locations create excessive delays. This intel extends beyond simple data points within the shipper-carrier ecosystem, and incorporates insights like:

Data alone is not actionable. For the connected TMS to be truly valuable, it must digest the data points and return concrete recommendations that draw a straight line to operational efficiency and profitability. This is where TMS solutions of the past evolve into those optimized for the future and the technology is no longer reserved for the largest carriers.

Industry Disruption

With 99% of truckload carriers being small- to mid-sized businesses, true industry disruption will be reached when even the smallest carriers can:

Outlook

Expect to see small carriers embrace the TMS solutions formerly reserved for mega-carriers: Gartner projects that $1.94 billion will be spent on TMS technology by 2022, and software as a service (SaaS) will account for 65% of the TMS market.

Ryan Camacho is director of business development at Axele.

Read the original:

Connected TMS Technology Is Reaching Mom-and-Pop Carriers - SupplyChainBrain

Posted in Tms

Pandemic spurs scientists to look closer at an experimental treatment for severe depression – CTV News

TORONTO -- COVID-19 hasnt just worsened mental health across the country its also cut access to specific medical treatments for those who struggle from severe depression, such as electroconvulsive therapy (ECT).

But the pressure of a pandemic has also spurred scientists to focus on some new therapies in order to keep helping patients, turning necessity into opportunity.

One patient who underwent an experimental therapy during the pandemic believes it could change lives, and even replace ECT altogether.

Kileen Sprock was in need of urgent help a month ago when she turned to a new treatment.

The human resources specialist had struggled with depression on and off for the past five years, undergoing various treatment.

But during COVID-19, she worsened.

I have been off work, and that has had a huge impact on my life, as you can imagine, Sprock told CTV News. Essentially, I am at home. If you've ever experienced depression, you know that there's pervasive sadness, there's a lack of confidence, a lack of self worth, fatigue, [you get] tired easily, and it was just a really difficult, difficult experience.

One of the medical therapies she had tried in the past was ECT, which is seen as a last resort for those suffering from depression so severe it will not respond to any other treatment.

But during the pandemic, ECT became more dangerous to administer.

Dr. Daniel Blumberger, director and chair of the Temerity Centre for Therapeutic Brain Intervention with CAMH, explained to CTV News that they had no choice but to cut down on patients due to the threat of COVID-19.

We were struck with a crisis, because when you do electroconvulsive therapy, there's a potential to generate aerosols when you have to give oxygen to patients, he said.

The treatment is performed under anesthesia, and involves small electric currents being passed through the brain. Patients are given oxygen through a mask while they are under, and they are asleep for around five to 10 minutes.

A psychiatrist, an anesthetist and other assistants have to be there for the process, all decked out in full PPE, all afraid of contracting the virus in the process.

But after doctors reduced the number of patients receiving ECT during the pandemic in order to cut down on virus risks for everyone involved, those patients were still in need of care.

We had to have another solution for these very sick and severely ill patients, Blumberger said.

When Sprocks mental health was worsening as a result of the pandemic, it was hard to find anywhere that would treat her due to hospitals cutting down on patients.

The hospitals were not really accepting new patients for different treatments, unless it was very very serious, Sprock said.

Thats when she heard of an emerging treatment.

I had tried so many different treatments, I had done ECT, dozens of antidepressants, Sprock said. "So this treatment was really, like, why not. Let's try it, I have nothing to lose.

A month ago at CAMH in Toronto, she was treated with an accelerated version of transcranial magnetic stimulation.

Repetitive transcranial magnetic stimulation (rTMS), a non-invasive procedure where an electromagnetic coil delivers magnetic pulses to stimulate the brain, is already approved for treating depression. In fact, Sprock had tried it before.

But usually the treatment is delivered once a day for six weeks or longer.

In recent years, scientists have been looking at delivering these magnetic pulses at higher volumes and on faster timelines to improve the treatment, such as intermittent theta-burst stimulation (iTBS), a more efficient version of rTMS that shortens sessions without sacrificing effectiveness. But iTBS still requires daily sessions over six weeks.

With COVID-19 creating pressure on all aspects of medical care, the question of speeding up these treatments was more pressing than ever.

Scientists and doctors decided to intensify and accelerate the treatment, delivering eight doses in a single day over one week, or in Sprocks case, two weeks.

And she noticed changes quickly.

I started to feel really, really good, she said. Probably about the fourth day of this treatment. It's hard to articulate, but I showed up for treatment that day, and I just felt brighter. And that had not happened with other treatments that I had been through.

Although accelerating the treatment is experimental still, preliminary studies suggest it works.

We think that the number of treatments per day has an effect that we're able to push the brain past what a once a day treatment would do, Blumberger said.

In the U.S. where the accelerated TMS was first tested researchers report up to 90 per cent remission for patients.

Study results from a randomized controlled trial are pending publication in the spring, according to the lead scientist, Nolan Williams, an assistant professor of Psychiatry and Behavioural Sciences at the Stanford University Medical Center.

We're looking at a therapy that works, Williams told CTV News.

Researchers speculate that the treatment is hitting the regions of the brain that are causing the depressive systems more accurately than before.

We use a special type of brain MRI to localize the exact position, Williams said. So we have kind of a personalized algorithm for finding the best spot, based off of the brain anatomy. That's probably a key difference.

Doctors in Vancouver have been trying accelerated TMS as well.

It's worked really, really, really well, Dr. Fidel Vila-Rodriguez, an assistant professor in the department of psychiatry at the University of British Columbia, told CTV News. That handful of patients that we've treated, they've all gotten better.

Being able to deliver treatment faster and over a shorter period has allowed more patients to get care even during the pandemic, Blumberger said.

Its been a big help, because they would have had to potentially wait for ECT or may not have been able to access it.

The logistics of ECT are also more complex than TMS, Vila-Rodriguez added, making it harder during COVID-19 due to the requirement of extra specialized staff and things such as anesthesia. Only one technician is required to physically deliver treatment with TMS.

You can treat a lot more people than you could treat with with ECT, Vila-Rodriguez said.

Williams pointed out that getting access to ECT can be very difficult in a non-pandemic year as well.

In the United States, only about 1.5 per cent of people that meet criteria for getting ECT actually get it, he said. So, 98.5 per cent people don't get it. One of the biggest reasons is [many] hospitals don't have ECT.

If accelerated TMS can help as much as ECT, it could be hugely important because its more accessible, and doesnt require as many people.

Some patients also may be wary to try ECT for a variety of reasons.

Mayo Clinic explains on its website that the treatment has a stigma due to how it was sometimes administered in the past, including high doses of electricity without anesthesia, leading to injury and serious memory loss.

In modern times, ECT is only administered with the patients informed consent, and 60 - 80 per cent of patients with depression achieve remission after treatment, according to the Centre for Addiction and Mental Health (CAMH), making it one of the most effective treatments for those with treatment-resistant mental illnesses.

But although it is safe, there are still some side-effects.

We need an alternative to ECT because even though electroconvulsive therapy is the most effective treatment for severe depression, unfortunately it's also associated with significant side-effects, and one of those side-effects, which is quite troublesome, is impact on memory, Vila-Rodriguez said.

Sprock said that one of the things she found remarkable about receiving accelerated TMS was how much less invasive it was compared to ECT, adding that her only side-effect so far has been headaches the day she received treatment.

ECT had some impact when she received it in the past, she said, but it did come at a cost.

I had memory loss that was quite severe for about a year, she said. Slowly, my memory did come back as time went on. I still have a little bit of memory issues, but I can't say that is too too bad. But with [accelerated TMS] theres been no impact to memory. Wonderful.

Sprock believes the therapy is so revolutionary that it could completely replace ECT, adding that if accelerated TMS had been around five years ago, she would have chosen it over trying ECT.

When shed been treated with the original TMS before, she had experienced slight improvements, which didnt last long. But this was night and day.

Sprock almost felt the way she used to before depression, she said.

I'm happy I'm chatty, she said. I'm back to being bubbly. So it really has changed my life. At this point, I do have six more months of follow up. They do assessments every week where they'll test to see how I'm doing, and based on where I am, I might go in for booster treatments. But otherwise, if all goes well in six months, I hope to be back to working.

Scientists are now planning a formal study to measure this accelerated treatment's effects to see if it truly is an alternative to ECT for some patients.

For now, it remains a last resort to help those in crisis during the pandemic.

Resources are available in communities across Canadafor anyone struggling with anxiety, depression or other mental health concerns.

See the rest here:

Pandemic spurs scientists to look closer at an experimental treatment for severe depression - CTV News

Posted in Tms

Across Systems’ Gerd Janiszewski on Selling the TMS Provider to Volaris Group – Slator

Translation management system provider, Across Systems, a household name for anyone involved in localizing technical documentation, has been acquired by Volaris Group, as the company reported in a January 14, 2021 press release. Focused on acquiring and developing vertical market software companies, Volaris Group is part of Toronto-listed Constellation Software. The financial terms of the transaction were undisclosed.

Volaris took the first step, said Gerd Janiszewski, Managing Director at Across, when asked about the genesis of the deal. Janiszewski told Slator that he was totally fascinated with Volaris fairly unique structure from the very beginning. For one thing, Volaris never sells the companies they acquire, he said.

Moreover, rather than integrating the companies they acquire, Volaris retains each organizations independence, according to the company website. This means the deal will likely change little for Across clients and partners in the short term except that, now, Across has a powerful backer to support the business.

As Janiszewski explained, the acquired business will typically operate independently inside Volaris and continue with their own brand and management team. He added, Volaris is focused on providing resources, best practices, and support to Across Systems.

Data and Research, Slator reports

40 pages on translation, localization industry M&A, venture funding. Valuations, PE funds, deal rationale, geo, investment theses.

Market opportunities for DACH-based Across (and translation tech providers, in general) are present worldwide throughout the supply chain, according to Janiszewski; from industries and enterprises to language service providers and freelancers.

As a pure-play technology provider, Across strengths square with those markets that demand full control over processes and data streams in a secure system, he said, adding that this is especially true of corporate clients within DACH, although they see great opportunities across the globe as well.

Were actively looking to broaden our offering through acquisitions with well-established, mature technologies, as well as new technologies

Asked for his views on the recent TMS funding and M&A wave (e.g., Memsource, Smartcat, Lokalise, Phrase), Janiszewski pointed out, Its obvious that we have two megatrends at the same time: concentration and the rise of new ideas, projects, technologies, which can add great value for users. And yes, we work on both. Were actively looking to broaden our offering through acquisitions with well-established, mature technologies, as well as new technologies, which we do not have in our existing offering.

According to the Across Managing Director, LSPs especially the Super Agencies are trying to strengthen their client relationships by using proprietary technologies that make it very hard (expensive) for clients to shift to another translation vendor. And, after a while, total costs for translation services for those clients are rising.

Data and Research, Slator reports

44-pages on how LSPs enter and scale in AI Data-as-a-service. Market overview, AI use cases, platforms, case studies, sales insights.

Meanwhile, Janiszewski noted, Other vendors are trying to gain access to client data in order to collect it and trying to generate and invoice additional services, which are purely based on the data of the clients. And the usage of this data certainly is not limited to the clients who own and paid for that data. This trend also tries to (as a by-product) eliminate traditional LSPs from the market.

As for Across, it will remain a pure tech company, Janiszewski said, providing clients valuable independence and full control over their data throughout the whole supply chain and at any time.

On the timing of the acquisition, he said Across was keen to join Volaris simply because they wanted to be part of a larger organization where they could make things happen and learn from a community of peers, which would not have been possible otherwise. The rationale behind the transaction was not purely financial, Janiszewski told Slator.

Market Intelligence

Access all of Slator's subscription services (SlatorSweep, SlatorPro & Research) with a company-wide license and save money.

Asked if an exit by Volaris was, at all, a possibility, Janiszewski reiterated, Volaris Group buys and holds companies. They never sell the companies they acquire.

No M&A advisers were involved in the deal. Osborn Maledon of Phoenix, Arizona and CMS Hasche Sigle of Frankfurt, Germany provided legal advice for Across.

View original post here:

Across Systems' Gerd Janiszewski on Selling the TMS Provider to Volaris Group - Slator

Posted in Tms

Axele hits outstanding milestone of 10000 loads since introduction less than 90 says ago – American Journal of Transportation

Rapid adoption of solution validates need for intelligent TMS for small to midsize truckload market

Axele, LLC, a Transportation Management System (TMS) company, announces that it has hit an unprecedented milestone of over 1,000 users registered and 10,000 loads managed in less than 90 days since introduction of the Axele TMS. The rapid adoption of Axele TMS validates the need for an intelligent TMS in the market targeting small to midsize truckload carriers.

Seeing this significant growth of users and loads since we started charging subscribers on November 2, 2020, the day the product became fully commercialized, shows that the truckload carrier market has long been underserved and in desperate need of a solution like this, said Ryan Camacho, Director, Business Development, Axele. With the Axele TMS, small to midsize carriers can reap the benefits of an optimized, automated, and connected TMS, with features and functionalities that enterprise TMS systems offer to large clients, at an affordable price.

Parent company Optym in June 2020 initially launched Axele TMS. From June through October 2020, Axele TMS users had used the tool at no charge. However, in November 2020, Axele launched its paid subscription model and has experienced impressive adoption by over 1,000 users, with 750 truck drivers hauling over 10,000 loads managed by the system.

The Axele TMS is built using Optyms proprietary algorithms that have successfully optimized flight schedules, railroad network planning, and linehaul planning for global logistics corporations. Axele TMS empowers small to medium-sized truckload carriers to increase operating income and reduce the time spent managing the business. The system is the first to deliver advanced optimization and automation technologies to carriers of all sizes capabilities that were once available only to large enterprise-sized trucking companies.

Read more here:

Axele hits outstanding milestone of 10000 loads since introduction less than 90 says ago - American Journal of Transportation

Posted in Tms

Best Comprehensive Report on Treasury Management System (TMS) Market 2021-2027| Cisco, Everbridge, HPE (Aruba), Cloud4Wi, Signify (Philips), CARTO …

A comprehensive report on Treasury Management System (TMS) Market was published by Research N Reports to understand the complete setup of Treasury Management System (TMS) Market industries. Effective qualitative and quantitative analysis techniques have been used to examine the data accurately. Variable factors that comprise basis for a successful business, such as vendors, sellers, as well as investors are analysed in the report. It focuses on size and framework of global Treasury Management System (TMS) Market sectors to understand the existing structure of several industries. Challenges faced by the industries and approaches adopted by them to overcome those threats has been included. This research report is helpful for both established businesses as well as start-ups in the market. Furthermore, the report is ideally and characteristically punctuated with illustrative presentation. Researchers of this report provide a detailed investigation of the historical records, current statistics, and future predictions. Factors contributing to success and acting as obstacles have both been discussed in equal measure.

Ask for sample copy of this report @https://www.researchnreports.com/request_sample.php?id=687320

Profiling Key players:Cisco, Everbridge, HPE (Aruba), Cloud4Wi, Signify (Philips), CARTO.

Highlights of the report:

In This Study, The Years Considered to Estimate the Size of Treasury Management System (TMS) Market are as Follows:

History Year: 2014-2020

Base Year: 2020

Estimated Year: 2021

Forecast Year 2021 to 2027

Ask for a discount on this report @ https://www.researchnreports.com/ask_for_discount.php?id=687320

Table of Contents:

Lastly, this report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights on the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market.

Get Detailed Information About Full Report before Buying @ https://www.researchnreports.com/enquiry_before_buying.php?id=687320

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

View original post here:

Best Comprehensive Report on Treasury Management System (TMS) Market 2021-2027| Cisco, Everbridge, HPE (Aruba), Cloud4Wi, Signify (Philips), CARTO ...

Posted in Tms

MEGALOBOX 2: NOMAD to Premiere in April 2021 on TOKYO MX & BS11 – Business Wire

TOKYO--(BUSINESS WIRE)--TMS Entertainment today announced that MEGALOBOX 2: NOMAD, the highly anticipated sequel to the internationally acclaimed anime series MEGALOBOX, will premiere in April 2021 on Japanese television networks TOKYO MX and BS11.

MEGALOBOX, a series based on Tomorrows Joe by Asao Takamori (Ikki Kajiwara) and Tetsuya Chiba, was originally released in 2018 to commemorate the 50th anniversary of the original manga title.

Teaser Trailer and Visuals RevealedThe teaser trailer and visuals have also been revealed ahead of the broadcast.Watch the teaser now: https://youtu.be/bjl0qMgrugQ

The striking teaser visual, drawn by the director Yo Moriyama, shows Joe standing with his gear covering the body full of scars. Seven years after Joes reign as the first Megalonia champion, we now find him calling himself Nomad. The accompanying teaser trailer reveals a glimpse of what had happened to Joe after the fateful match with Yuri in MEGALOBOX.

ABOUT MEGALOBOX 2: NOMADIn the end, Gearless Joe was the one that reigned as the champion of Megalonia, a first ever megalobox tournament. Fans everywhere were mesmerized by the meteoric rise of Joe who sprung out from the deepest underground ring to the top in mere three months and without the use of gear. Seven years later, Gearless Joe was once again fighting in underground matches. Adorned with scars and once again donning his gear, but now known only as NomadWEB: https://megalobox.com/ Twitter: https://twitter.com/joe50_megalobox

STAFFOriginal Concept: Tomorrows JoeOriginal Comic Books Created by Asao Takamori, Tetsuya Chiba / Published by Kodansha.Director / Concept Designer: Yo MoriyamaScenario: Katsuhiko Manabe, Kensaku KojimaCharacter Designer: Ayumi KurashimaSub Character Designer: Naomi KanedaMusic: mabanuaAnimation production: TMS Entertainment Co., Ltd.Produced by MEGALOBOX2 Project

CASTJoe / NOMAD: Yoshimasa HosoyaGANSAKU NANBU: Shiro SaitoYURI: Hiroki YasumotoSACHIO: Michiyo Murase

Asao Takamori, Tetsuya Chiba/Kodansha/MEGALOBOX2 project. All Rights Reserved.

About TMS EntertainmentBy maintaining a balance of creativity and business production, TMS Entertainment provides a one-stop shop for services from IP creation to consumer satisfaction improvement, centered around its animation production, licensing, and content businesses. TMS Entertainment has continuously produced much-loved anime titles in Japan, including "Lupin the 3rd," "Dr. STONE," and MEGALOBOX while connecting its library of over 12,000 episodes across a total of 420 titles to its global business.

WEB: https://www.tms-e.co.jp/global/ Twitter: https://twitter.com/tmsanime Facebook: https://www.facebook.com/AnimeTMS Instagram: https://www.instagram.com/tmsanime/

Read the original here:

MEGALOBOX 2: NOMAD to Premiere in April 2021 on TOKYO MX & BS11 - Business Wire

Posted in Tms

Global Transportation Management System Market Report 2021: Opportunities in the Increasing Adoption of Cloud-Based Technology and Industry 4.0 -…

DUBLIN, Jan. 28, 2021 /PRNewswire/ -- The "Global Transportation Management System (2020-2025) by Component, Transportation Mode, Deployment, Organisation Type, End-user, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Transportation Management Systems Market is estimated to be USD 7.4 Bn in 2020 and is expected to reach USD 17.7 Bn by 2025, growing at a CAGR of 19%.

The major driver for the Transportation Management System market is technological advancements in the transportation and logistics industry. The majority of the companies in the world are adopting digital technologies for creating unmatched opportunities for operational planning and a richer client experience.

Advanced technologies like Internet of things, Artificial intelligence, and big data analytics are driving the transportation management system. It also allows for smarter and efficient transport and logistics operations. Another major driver is exponential growth in the e-commerce industry, which improves the growth of the market.

However, the shortage of experienced professionals and higher implementation and maintenance costs hamper the market from growing during the forecast period.

Segments CoveredBased on Component, the global Transportation Management System is segmented into Solutions and Services. The Solutions is further divided into Planning and Execution, Order Management, Audit, Payment and Claims, Analytics and Reporting, and Routing and Tracking. The Service component is further divided into Consulting, Integration, and Implementation, and Support and Maintenance. The Consulting service segment is expected to grow at a higher rate. It is helpful for end-users because some of the companies do not have the experienced to understand the complexities involved in configuring TMS.

Based on Transportation Mode, the Global Transportation Management System is segmented into Roadways, Railways, Airways, and Maritime. The Roadways segment is expected to grow during the forecast period. It is the most prevalent mode of transport. Roadway mode is a relatively cheaper and flexible mode, making it possible to load and unload anywhere.

Based on Deployment Type, the Cloud segment holds the maximum share in TMS. The emergence of cloud-based technologies is anticipated to trigger the replacement of aging conventional TMS solutions. The recent development in software such as machine learning and predictive analytics, 3-D printing anticipate the growth and opportunities for the key players in the transportation management system market.

Based on Organisation Type, the Large Enterprise holds the maximum share in the market. The TMS offers a centralized system with several features like carrier tracking, order management, billing and accounts settlement, etc. Large enterprises invest heavily in TMS to increase their overall productivity and efficiency. Also, advanced technologies and innovative solutions in TMS helps enterprises to grow rapidly.

Based on End User, the Manufacturing segment holds the largest share in the market. Most of the manufacturing companies are adopting transportation solutions for cost reduction. TMS helps in tracking and managing inventory, route optimization, and minimizing shipment/freight costs. It also reduces the operational cost. It increases visibility and control over the transportation chain and unscheduled downtime and improves product performance.

Based on Region, North America is expected to hold the largest market share in the market. This is because of the adoption of advanced technologies and cloud computing. They have an advanced IT infrastructure, which reduces the operational expenditure through various advancement in technologies.

Asia-Pacific is also expected to witness a high growth rate. It is mainly due to the increasing international trade, increasing penetration of smartphone use coupled with increasing disposable income. These factors propel the growth of eCommerce in these regions. Therefore, proper TMS will be required to cater to a broad range of customers.

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Overview4.1 Introduction 4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.2.4 Challenges4.3 Trends

5 Market Analysis5.1 Porter's Five Forces Analysis5.2 Impact of COVID-195.3 Ansoff Matrix Analysis

6 Global Transportation Management System Market, By Component6.1 Introduction6.2 Solutions 6.2.1 Planning and Execution 6.2.2 Order Management6.2.3 Audit, Payment, and Claims 6.2.4 Analytics and Reporting 6.2.5 Routing and Tracking6.3 Services 6.3.1 Consulting 6.3.2 Integration and Implementation 6.3.3 Support and Maintenance

7 Global Transportation Management System Market, By Transportation Mode7.1 Introduction7.2 Roadways7.3 Railways 7.4 Airways 7.5 Maritime

8 Global Transportation Management System Market, By Deployment Type8.1 Introduction8.2 On-Premises8.3 Cloud

9 Global Transportation Management System Market, By Organisation Type9.1 Introduction9.2 Large Enterprises9.3 Small and Medium-Sized Enterprises

10 Global Transportation Management System Market, By End User10.1 Introduction10.2 Retail10.3 Healthcare and Pharmaceutical 10.4 Manufacturing 10.5 Transportation and Logistics 10.6 Energy and Utilities 10.7 Government 10.8 Other

11 Global Transportation Management System Market, By Geography11.1 Introduction11.2 North America11.2.1 US11.2.2 Canada11.2.3 Mexico11.3 South America11.3.1 Brazil11.3.2 Argentina11.4 Europe11.4.1 UK11.4.2 France11.4.3 Germany11.4.4 Italy11.4.5 Spain11.4.6 Rest of Europe11.5 Asia-Pacific11.5.1 China11.5.2 Japan11.5.3 India11.5.4 Indonesia11.5.5 Malaysia11.5.6 South Korea11.5.7 Australia11.5.8 Russia11.5.9 Rest of APAC11.6 Rest of the World11.6.1 Qatar11.6.2 Saudi Arabia11.6.3 South Africa11.6.4 United Arab Emirates11.6.5 Latin America

12 Competitive Landscape12.1 IGR Competitive Quadrant12.2 Market Share Analysis12.3 Competitive Scenario12.3.1 Mergers & Acquisitions12.3.2 Agreements, Collaborations, & Partnerships12.3.3 New Product Launches & Enhancements12.3.4 Investments & Fundings

13 Company Profiles13.1 Oracle 13.2 SAP 13.3 Manhattan Associates13.4 C.H. Robinson 13.5 Trimble13.6 Blujay Solutions13.7 Mercurygate International 13.8 Blue Yonder 13.9 Transplace 13.10 Descartes Systems Group 13.11 E2OPEN 13.12 Alpega Group13.13 3GTMS13.14 3T Logistics & Technology Group13.15 Globaltranz13.16 Inmotion Global13.17 Vtradex13.18 MP Objects13.19 Logistically13.20 One Network Enterprises13.21 Elemica13.22 Tailwind Transportation Software13.23 Intellitrans13.24 Allotrac

For more information about this report visit https://www.researchandmarkets.com/r/43esrx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Link:

Global Transportation Management System Market Report 2021: Opportunities in the Increasing Adoption of Cloud-Based Technology and Industry 4.0 -...

Posted in Tms

The New World of Logistics – PRNewswire

ATLANTA, Feb. 2, 2021 /PRNewswire/ --TranMazon LLC is excited to announce the launch of their New Transportation Management System and Grocery Delivery System, their Transportation Management System (TMS) is designed to allow their Virtual Branch Partners (VBP) to work from home in a very professional manner accordingly to their CEO and President Milton L. Collier.

Entry of New World of Logistics amid COVID-19 Pandemic

Accordingly, to Milton L. Collier, CEO and President of TranMazon the COVID-19 pandemic has put forward a spectrum of challenges, but logistics is still full speed ahead. As supply chains across the world continue to be burdened with soaring demands for shipping and moving products companies are expected to formulate an efficient model to address these demands.

At present, participants within the last mile delivery transportation market are increasingly examining different methods that are likely to minimize the costs of transportation of goods in the last leg of the journey.

Advancements in technology like TranMazon Transportation Management System (TMS) are likely to drive innovations. The flourishing e-Commerce sector has presented significant opportunities for participants in the last mile delivery transportation market. Currently, pilot testing of new technologies and new transportation models around the world has increased at a rapid pace a trend that is likely to continue during the assessment period. Some of the factors that are likely to enable the growth of the last mile delivery transportation market include the adoption of diversified last mile services, assessment of incurring costs of sold goods, and expansion of the omni-channel inventory selection.

TranMazon LLC is genuinely excited and anticipated to expand their operation with their new Transportation Management System (TMS) and hire more Virtual Branch Partners (VBP) to work from home all over the USA, owing to a rise in the middle-class population across the globe that has led to an increase in consumption and hence, is expected to boost the volume of goods transported.

Please review TranMazon website; http://www.TranMazon.com for more details about their company and services provided.

TranMazon is a Delivery Service Partner with Amazon and Logistics Industry Services Provider. Our goal is to provide "Best in Class" services. It begins with the courtesy and helpfulness of our Customer Service Team. We believe in treating our customers and employees with respect and integrity. It's a reflection of the pride we take in presenting solutions that work. Failure to deliver for our customers is not acceptable. That's why we bring a "World Class" attitude to our jobs each day.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE TranMazon LLC

http://www.TranMazon.com

Read more here:

The New World of Logistics - PRNewswire

Posted in Tms

Transcranial magnetic stimulation (TMS): Hope for stubborn …

Depression is the leading cause of disability in the United States among people ages 15 to 44. While there are many effective treatments for depression, first-line approaches such as antidepressants and psychotherapy do not work for everyone. In fact, approximately two-thirds of people with depression dont get adequate relief from the first antidepressant they try. After two months of treatment, at least some symptoms will remain for these individuals, and each subsequent medication tried is actually less likely to help than the one prior.

What can people with depression do when they do not respond to first-line treatments? For several decades, electroconvulsive therapy (ECT or shock therapy) was the gold standard for treatment-resistant depression. In fact, ECT is still considered to be the most potent and effective treatment for this condition, and it continues to be used regularly across the country. For many people with depression, however, ECT can be too difficult to tolerate due to side effects on memory and cognition. For those individuals and the many others who have had an inadequate response to medications and therapy alone, there is a newer treatment option called transcranial magnetic stimulation (TMS).

Transcranial magnetic stimulation, or TMS, is a noninvasive form of brain stimulation. TMS devices operate completely outside of the body and affect central nervous system activity by applying powerful magnetic fields to specific areas of the brain that we know are involved in depression. TMS doesnt require anesthesia and it is generally exceptionally well tolerated as compared to the side effects often seen with medications and ECT. The most common side effect is headache during or after treatment. A rare but serious side effect is seizures, and TMS may not be appropriate for people at high risk such as those with epilepsy, a history of head injury, or other serious neurologic issues.

Approximately 50% to 60% of people with depression who have tried and failed to receive benefit from medications experience a clinically meaningful response with TMS. About one-third of these individuals experience a full remission, meaning that their symptoms go away completely. It is important to acknowledge that these results, while encouraging, are not permanent. Like most other treatments for mood disorders, there is a high recurrence rate. However, most TMS patients feel better for many months after treatment stops, with the average length of response being a little more than a year. Some will opt to come back for subsequent rounds of treatment. For individuals who do not respond to TMS, ECT may still be effective and is often worth considering.

TMS therapy is an intensive treatment option requiring sessions that occur five days a week for several weeks. Each session may last anywhere from 20 to 50 minutes, depending on the device and clinical protocol being used. When patients arrive, they may briefly check in with a technician or doctor and then begin the stimulation process. The technician will determine the ideal stimulation intensity and anatomical target by taking advantage of a landmark in the brain called the motor cortex. By first targeting this part of the brain, the team can determine where best to locate the stimulation coil as it relates to that individuals brain and how intensely it must fire in order to achieve adequate stimulation. Calculations are then applied to translate this data toward finding the dorsolateral prefrontal cortex, the brain target with the greatest evidence of clinical effectiveness and an area known to be involved in depression. Though one session may be enough to change the brains level of excitability, relief isnt usually noticeable until the third, fourth, fifth, or even sixth week of treatment.

TMS is being studied extensively across disorders and even disciplines with the hope that it will evolve into new treatments for neurological disorders, pain management, and physical rehabilitation in addition to psychiatry. There are currently large clinical trials looking at the effectiveness of TMS in conditions such as pediatric depression, bipolar disorder, obsessive-compulsive disorder, smoking cessation, and post-traumatic stress disorder. While promising avenues for research, TMS for these conditions is not yet approved and would be considered off-label.

See more here:

Transcranial magnetic stimulation (TMS): Hope for stubborn ...

Posted in Tms

Transcranial magnetic stimulation – Mayo Clinic

Overview

Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when other depression treatments haven't been effective.

This treatment for depression involves delivering repetitive magnetic pulses, so it's called repetitive TMS or rTMS.

Close

In transcranial magnetic stimulation (TMS), an electromagnetic coil placed against the scalp creates a magnetic field that stimulates certain areas of the brain.

During an rTMS session, an electromagnetic coil is placed against your scalp near your forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of your brain involved in mood control and depression. It's thought to activate regions of the brain that have decreased activity in depression.

Though the biology of why rTMS works isn't completely understood, the stimulation appears to impact how the brain is working, which in turn seems to ease depression symptoms and improve mood.

There are different ways to perform the procedure, and techniques may change as experts learn more about the most effective ways to perform treatments.

Depression is a treatable condition, but for some people, standard treatments aren't effective. Repetitive TMS is typically used when standard treatments such as medications and talk therapy (psychotherapy) don't work.

Repetitive TMS is a noninvasive form of brain stimulation used for depression. Unlike vagus nerve stimulation or deep brain stimulation, rTMS does not require surgery or implantation of electrodes. And, unlike electroconvulsive therapy (ECT), rTMS doesn't cause seizures or require sedation with anesthesia.

Generally, rTMS is considered safe and well-tolerated. However, it can cause some side effects.

Side effects are generally mild to moderate and improve shortly after an individual session and decrease over time with additional sessions. They may include:

Your doctor can adjust the level of stimulation to reduce symptoms or may recommend that you take an over-the-counter pain medication before the procedure.

Serious side effects are rare. They may include:

More study is needed to determine whether rTMS may have any long-term side effects.

Before having rTMS, you may need a:

These evaluations help make sure that rTMS is safe and a good option for you.

Tell your doctor or mental health provider if:

Repetitive TMS isn't invasive, doesn't require anesthesia and can be performed on an outpatient basis. You don't need to arrange for someone to drive you home after treatment unless, for the first treatment, you prefer a driver until you get a sense of how you'll feel afterward.

Before considering treatment, check with your health insurance company to see whether rTMS is covered. Your policy may not cover it.

Repetitive TMS is usually done in a doctor's office or clinic. It requires a series of treatment sessions to be effective. Generally, sessions are carried out daily, five times a week for four to six weeks.

Before treatment begins, your doctor will need to identify the best place to put the magnets on your head and the best dose of magnetic energy for you. Your first appointment typically lasts about 60 minutes.

Most likely, during your first appointment:

Once the coil placement and dose are identified, you're ready to begin. Here's what to expect during each treatment:

You can return to your normal daily activities after your treatment. Typically, between treatments, you can expect to work and drive.

If rTMS works for you, your depression symptoms may improve or go away completely. Symptom relief may take a few weeks of treatment.

The effectiveness of rTMS may improve as researchers learn more about techniques, the number of stimulations required and the best sites on the brain to stimulate.

After completion of an rTMS treatment series, standard care for depression such as medication and psychotherapy may be recommended as ongoing treatment.

It's not yet known if maintenance rTMS sessions will benefit your depression. This involves continuing treatment when you are symptom-free with the hope that it will prevent the return of symptoms.

However, if your depression improves with rTMS, and then later you have another episode of symptoms, your rTMS treatment can be repeated. This is called re-induction. Some insurance companies will cover re-induction.

If your symptoms improve with rTMS, discuss ongoing or maintenance treatment options for your depression with your doctor.

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

Nov. 27, 2018

See more here:

Transcranial magnetic stimulation - Mayo Clinic

Posted in Tms

Transcranial magnetic stimulation – Wikipedia

Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.[1]:3[2]

TMS has shown diagnostic and therapeutic potential in the central nervous system with a wide variety of disease states in neurology and mental health, with research still evolving.[3][4][5][6][7][8][9][10]

Adverse effects of TMS are rare, and include fainting and seizure.[11] Other potential issues include discomfort, pain, hypomania, cognitive change, hearing loss, and inadvertent current induction in implanted devices such as pacemakers or defibrillators.[11]

TMS is non-invasive, and does not require surgery or electrode implantation. Its use can be divided into diagnostic and therapeutic applications. Effects vary based on frequency and intensity of the magnetic pulses as well as the length of the train, which affects the total number of pulses given.[citation needed] TMS treatments are now approved by the FDA in the USA and by NICE in the UK for the treatment of depression and are predominantly provided by private clinics.

TMS can be used clinically to measure activity and function of specific brain circuits in humans, most commonly with single or paired magnetic pulses.[3] The most widely accepted use is in measuring the connection between the primary motor cortex of the central nervous system and the peripheral nervous system to evaluate damage related to past or progressive neurologic insult.[3][13][14][15]

Repetitive high frequency TMS (rTMS) has shown diagnostic and therapeutic potential with the central nervous system in a variety of disease states, particularly in the fields of neurology and mental health.[3][4][5][7][8][9][10]

Although TMS is generally regarded as safe, risks are increased for therapeutic rTMS compared to single or paired diagnostic TMS.[16] Adverse effects generally increase with higher frequency stimulation.[11]

The greatest immediate risk from TMS is fainting, though this is uncommon. Seizures have been reported, but are rare.[11][17][18] Other adverse effects include short term discomfort, pain, brief episodes of hypomania, cognitive change, hearing loss, impaired working memory, and the induction of electrical currents in implanted devices such as cardiac pacemakers.[11]

During the procedure, a magnetic coil is positioned at the head of the person receiving the treatment using anatomical landmarks on the skull, in particular the inion and nasion.[12] The coil is then connected to a pulse generator, or stimulator, that delivers electric current to the coil.[2]

TMS uses electromagnetic induction to generate an electric current across the scalp and skull.[19][20] A plastic-enclosed coil of wire is held next to the skull and when activated, produces a magnetic field oriented orthogonal to the plane of the coil. The magnetic field can then be directed to induce an inverted electric current in the brain that activates nearby nerve cells in a manner similar to a current applied superficially at the cortical surface.[21]

The magnetic field is about the same strength as an MRI, and the pulse generally reaches no more than 5 centimeters into the brain, unless using a modified coil and technique for deeper stimulation.[20]

From the BiotSavart law,

it has been shown that a current through a wire generates a magnetic field around that wire. Transcranial magnetic stimulation is achieved by quickly discharging current from a large capacitor into a coil to produce pulsed magnetic fields between 2 and 3 Tesla in strength.[22] Directing the magnetic field pulse at a targeted area in the brain causes a localized electrical current which can then either depolarize or hyperpolarize neurons at that site. The magnetic flux generated by the current causes its own electric field, as explained by the Maxwell-Faraday equation,

This electric field causes a change in transmembrane currents resulting in depolarization or hyperpolarization of neurons, causing them to be more or less excitable, respectively.[22]

Deep TMS can reach up to 6cm into the brain to stimulate deeper layers of the motor cortex, such as that which controls leg motion. The path of this current can be difficult to model because the brain is irregularly shaped with variable internal density and water content, leading to a nonuniform magnetic field strength and conduction throughout its tissues.[23]

The effects of TMS can be divided based on frequency, duration and intensity (amplitude) of stimulation:[24]

Most devices use a coil shaped like a figure-eight to deliver a shallow magnetic field that affects more superficial neurons in the brain.[28] Differences in magnetic coil design should be considered when comparing results, with important elements including the type of material, geometry and specific characteristics of the associated magnetic pulse.

The core material may be either a magnetically inert substrate ('air core'), or a solid, ferromagnetically active material ('solid core'). Solid cores result in more efficient transfer of electrical energy to a magnetic field and reduce energy loss to heat, and so can be operated with the higher volume of therapy protocols without interruption due to overheating. Varying the geometric shape of the coil itself can cause variations in focality, shape, and depth of penetration. Differences in coil material and its power supply also affect magnetic pulse width and duration.[29]

A number of different types of coils exist, each of which produce different magnetic fields. The round coil is the original used in TMS. Later, the figure-eight (butterfly) coil was developed to provide a more focal pattern of activation in the brain, and the four-leaf coil for focal stimulation of peripheral nerves. The double-cone coil conforms more to the shape of the head.[30] The Hesed (H-core), circular crown and double cone coils allow more widespread activation and a deeper magnetic penetration. They are supposed to impact deeper areas in the motor cortex and cerebellum controlling the legs and pelvic floor, for example, though the increased depth comes at the cost of a less focused magnetic pulse.[11]

Luigi Galvani (1737-1798) undertook research on the effects of electricity on the body in the late-eighteenth century and laid the foundations for the field of electrophysiology.[31] In the 1830s Michael Faraday (1791-1867) discovered that an electrical current had a corresponding magnetic field, and that changing one could induce its counterpart.[32]

Work to directly stimulate the human brain with electricity started in the late 1800s, and by the 1930s the Italian physicians Cerletti and Bini had developed electroconvulsive therapy (ECT).[31] ECT became widely used to treat mental illness, and ultimately overused, as it began to be seen as a panacea. This led to a backlash in the 1970s.[31]

In 1980 Merton and Morton successfully used transcranial electrical stimulation (TES) to stimulate the motor cortex. However, this process was very uncomfortable, and subsequently Anthony T. Barker began to search for an alternative to TES.[33] He began exploring the use of magnetic fields to alter electrical signaling within the brain, and the first stable TMS devices were developed in 1985.[31][32] They were originally intended[by whom?] as diagnostic and research devices, with evaluation of their therapeutic potential being a later development.[31][32] The United States' FDA first approved TMS devices in October 2008.[31]

TMS has shown potential with neurologic conditions such as Alzheimer's disease,[4] amyotrophic lateral sclerosis,[4][34] persistent vegetative states,[4] epilepsy,[4][35] stroke related disability,[4][11][14][15][36][37] tinnitus,[4][38] multiple sclerosis,[4] schizophrenia,[4][10] and traumatic brain injury.[39]

With Parkinson's disease, early results suggest that low frequency stimulation may have an effect on medication associated dyskinesia, and that high frequency stimulation improves motor function.[40] The most effective treatment protocols appear to involve high frequency stimulation of the motor cortex, particularly on the dominant side,[41] but with more variable results for treatment of the dorsolateral prefrontal cortex.[42] It is less effective than electroconvulsive therapy for motor symptoms, though both appear to have utility.[43][44][45] Cerebellar stimulation has also shown potential for the treatment of levodopa associated dyskinesia.[46]

In psychiatry, it has shown potential with anxiety disorders, including panic disorder[47] and obsessive-compulsive disorder (OCD).[4] The most promising areas to target for OCD appear to be the orbitofrontal cortex and the supplementary motor area.[48] Older protocols that targeted the prefrontal dorsal cortex were less successful.[49] It has also been studied with autism,[50] substance abuse,[4] addiction,[4][51] and posttraumatic stress disorder (PTSD).[4] For treatment-resistant major depressive disorder, high-frequency (HF) rTMS of the left dorsolateral prefrontal cortex (DLPFC) appears effective and low-frequency (LF) rTMS of the right DLPFC has probable efficacy.[4][5][7][8][9]

TMS can also be used to map functional connectivity between the cerebellum and other areas of the brain.[52]

Mimicking the physical discomfort of rTMS with placebo to discern its true effect is a challenging issue in research.[4][11][53][54] It is difficult to establish a convincing placebo for TMS during controlled trials in conscious individuals due to the neck pain, headache and twitching in the scalp or upper face associated with the intervention.[4][11] In addition, placebo manipulations can affect brain sugar metabolism and MEPs, which may confound results.[55] This problem is exacerbated when using subjective measures of improvement.[11] Placebo responses in trials of rTMS in major depression are negatively associated with refractoriness to treatment.[56]

A 2011 review found that most studies did not report unblinding. In the minority that did, participants in real and sham rTMS groups were not significantly different in their ability to correctly guess their therapy, though there was a trend for participants in the real group to more often guess correctly.[57]

TMS research in animal studies is limited due to its early FDA approval for treatment-resistant depression, limiting development of animal specific magnetic coils.[58]

Nexstim obtained 510(k) FDA clearance for the assessment of the primary motor cortex for pre-procedural planning in December 2009[59] and for neurosurgical planning in June 2011.[60]

In 2008, the US Food and Drug Administration authorized the use of rTMS as a treatment for depression that has not improved with other measures.[61][62] A number of deep TMS have received FDA 510k clearance to market for use in adults with treatment resistant major depressive disorders.[63][64][65][66][67] The Royal Australian and New Zealand College of Psychiatrists has endorsed rTMS for treatment resistant major depressive disorder (MDD).[68]

The use of single-pulse TMS was approved by the FDA for treatment of migraines in December 2013.[69] It is approved as a Class II medical device under the "de novo pathway".[70][71]

In the European Economic Area, various versions of Deep TMS H-coils have CE marking for Alzheimer's disease,[72] autism,[72] bipolar disorder,[73] epilepsy [74] chronic pain[73] major depressive disorder[73] Parkinson's disease,[41][75] posttraumatic stress disorder (PTSD),[73] schizophrenia (negative symptoms)[73] and to aid smoking cessation.[72] One review found tentative benefit for cognitive enhancement in healthy people.[76]

In August 2018, the US Food and Drug Administration authorized the use of TMS in the treatment of obsessive-compulsive disorder (OCD).[77]

In 2013, several commercial health insurance plans in the United States, including Anthem, Health Net, and Blue Cross Blue Shield of Nebraska and of Rhode Island, covered TMS for the treatment of depression for the first time.[78][79][80][81] In contrast, UnitedHealthcare issued a medical policy for TMS in 2013 that stated there is insufficient evidence that the procedure is beneficial for health outcomes in patients with depression. UnitedHealthcare noted that methodological concerns raised about the scientific evidence studying TMS for depression include small sample size, lack of a validated sham comparison in randomized controlled studies, and variable uses of outcome measures.[82] Other commercial insurance plans whose 2013 medical coverage policies stated that the role of TMS in the treatment of depression and other disorders had not been clearly established or remained investigational included Aetna, Cigna and Regence.[83][84][85]

Policies for Medicare coverage vary among local jurisdictions within the Medicare system,[86] and Medicare coverage for TMS has varied among jurisdictions and with time. For example:

The United Kingdom's National Institute for Health and Care Excellence (NICE) issues guidance to the National Health Service (NHS) in England, Wales, Scotland and Northern Ireland. NICE guidance does not cover whether or not the NHS should fund a procedure. Local NHS bodies (primary care trusts and hospital trusts) make decisions about funding after considering the clinical effectiveness of the procedure and whether the procedure represents value for money for the NHS.[94]

NICE evaluated TMS for severe depression (IPG 242) in 2007, and subsequently considered TMS for reassessment in January 2011 but did not change its evaluation.[95] The Institute found that TMS is safe, but there is insufficient evidence for its efficacy.[95]

In January 2014, NICE reported the results of an evaluation of TMS for treating and preventing migraine (IPG 477). NICE found that short-term TMS is safe but there is insufficient evidence to evaluate safety for long-term and frequent uses. It found that evidence on the efficacy of TMS for the treatment of migraine is limited in quantity, that evidence for the prevention of migraine is limited in both quality and quantity.[96]

Subsequently, in 2015, NICE approved the use of TMS for the treatment of depression in the UK and IPG542 replaced IPG242.[97] NICE said "The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns. The evidence on its efficacy in the short-term is adequate, although the clinical response is variable. Repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit."

A single TMS session for depressive disorders averages US$350. A full course of treatment could cost between US$6,000 and US$12,000, depending on the number of treatments.[98][26]

Manufacturers of the devices include Brainsway, Deymed, MagVenture, Mag&More, Magstim, Nexstim, Neuronetics, Neurosoft.[citation needed] Current UK providers include a few NHS Trusts and a private operator, Smart TMS. In Cyprus FDA approved treatments for depression and OCD are provided by Cyprus rTMS [99].Also the Cyprus Technological University uses rTMS in research [100]

See the rest here:

Transcranial magnetic stimulation - Wikipedia

Posted in Tms